Toreforant

DB12522InvestigationalSmall molecule

Toreforant has been used in trials studying the treatment of Asthma, Psoriasis, Hepatic Impairment, and Rheumatoid Arthritis.

Chemical structure of Toreforant
Mechanism
Curator reviewed
Formula / weight
C23H32N6 · 392.551 g/mol (avg)
Code names
JNJ-38518168

Resolves to

Compound
UNIIU6LA7G393XCAS952494-46-1ChEMBLCHEMBL3301609PubChem23650961
Structure
InChIKeyFCRFVPZAXGJLPW-UHFFFAOYSA-NSMILESCN1CCC(CCCNC2=NC=C(C3=NC4=C(C)C=C(C)C=C4N3)C(C)=N2)CC1
Targets
Q9H3N8HRH4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Toreforant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In